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Introduction
The major hallmark of inflammation is the recruitment and activa-
tion of leucocytes, especially polymorphonuclear neutrophils
(PMNs), which results from a complex interplay among these cells
and the vascular endothelium [1–3] and accounts for destruction
of foreign pathogens on one hand, and breakdown and remodel-
ling of inflamed tissues on the other hand [4]. Inflammation is trig-
gered and sustained by pro-inflammatory cytokines as well as
prostaglandins and gaseous radicals, such as nitric oxide [4–6],
which are produced locally by the inflammation-induced enzymes
cyclooxygenase-2 (COX-2) and nitric oxide synthase (iNOS). Most
of the classical anti-inflammatory drugs target the endogenous
production of these pro-inflammatory mediators.
In this context, the sulphated proteoglycan heparin can be also
regarded as a non-conventional anti-inflammatory molecule, as it
has several biological actions independent of its well-known anti-
coagulant activity, including the modulation of extracellular matrix
synthesis, cell proliferation, angiogenesis and inflammation
[7–11]. In particular, heparin has been shown to inhibit pro-
inflammatory cytokine production by human monocytes stimulated
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by lipopolysaccharide or interferon- [12]. On these grounds, in
recent years, considerable efforts have been made to identify the
molecular domains of heparin responsible for its anti-inflamma-
tory properties and to develop synthetic derivatives with low or no
anti-coagulant properties and clear-cut anti-inflammatory effects
[13]. In animal models of inflammation, such as acute peritonitis
and organ-specific ischemia reperfusion, these anti-inflammatory
heparin-like molecules effectively inhibited leucocyte adhesion
and migration [13].
We have recently studied the anti-inflammatory properties of K5
polysaccharide obtained from Escherichia coli strain 010:K5:H4.
This is a polymer of the D-glucuronic acid and N-acetyleparoson
disaccharide unit, the precursor of heparin and heparan sulphate.
This structural affinity makes the K5 polysaccharide an optimal
precursor for the synthesis of sulphated heparin semi-synthetic
derivatives. In particular, the low molecular weight compound K5-N,
OS epi (K5NOSepiLMW) lacks appreciable anti-thrombotic activity
and is able to inhibit the production of pro-inflammatory cytokines
from human lipopolysaccharide-stimulated mononuclear cells,
without influencing other anti-inflammatory cytokines such as
interleukin (IL)-10 [14]. The aim of the present study is to evaluate
the effects of K5NOSepiLMW in a widely used in vivo model 
of acute inflammation in the rat, namely carrageenan-induced
pleurisy, whose cellular and molecular mechanisms are well 
characterized [15–21].
Materials and methods
Materials
Primary rabbit polyclonal anti-nitrotyrosine (NT) antiserum, biotin-con-
jugated goat anti-rabbit IgG, and avidin-biotin peroxidase complex were
obtained from Upstate Biotech (DBA, Milan, Italy). Rabbit polyclonal
anti-COX-2 and anti-iNOS antisera were from Cayman Chemicals (Ann
Arbor, MI, USA). Celecoxib was from LC Laboratories (Woburn, MA,
USA). Unless otherwise stated, all other reagents and compounds used
were obtained from Sigma (Milan, Italy). The semi-synthetic low molec-
ular weight heparin polysaccharide K5-N,OSepi (K5NOSepiLMW) was
provided by INALCO RSM Research Center, Montale, Italy, as reported
previously [14].
Carrageenan-induced pleurisy and drug 
treatments
Male Wistar albino rats (Charles River, Milan, Italy), weighing 250–300 g,
were housed in a controlled environment and provided with standard
rodent chow and water. The experimental protocols were designed in com-
pliance with the Italian and the European Community regulations on animal
experimentation for scientific purposes (D.M. 116192; O.J. of E.C. L358/1
12/18/1986).
Rats were anaesthetized with sodium pentobarbital (Abbott, Latina,
Italy; 50 mg/kg b.wt., intraperitoneally) and submitted to a skin incision at
the sixth left intercostal space to access the pleural cavity. The animals
were then treated as described below.
Briefly, 48 rats were divided in seven groups, eight animals each:
(1) Sham-operated control animals, injected intrapleurally with 0.2 ml
sterile saline;
(2) Carrageenan-treated animals, injected intrapleurally with -car-
rageenan, 1% w/v in 0.2 ml sterile saline;
(3)–(5) Animals pre-treated with K5NOSepiLMW, given intrapleurally at
the doses of 0.1, 0.5 or 1 mg/kg b.wt. 30 min. before car-
rageenan;
(6) Animals treated with B4/110, a biologically inactive non-sulphated
polysaccharide compound used as negative control molecule, given
intrapleurally at the dose of 1 mg/kg b.wt. 30 min. before car-
rageenan;
(7) Animals treated with celecoxib, a COX-2 inhibitor used as reference
anti-inflammatory drug, given intrapleurally at the dose of 1 mg/kg
b.wt. 30 min. before carrageenan. This dose was consistent with
that required to abrogate COX-2 activity [19].
After the injections, the skin incision was closed with a suture. Four
hours later, the animals were killed with a lethal dose of sodium pentobar-
bital. The chest was carefully opened and the pleural cavity was rinsed with
2 ml saline containing heparin (5 IU/ml) and indomethacin (10 g/ml). The
total volume of exudate and washing solution was collected. The exudates
contaminated with blood were discarded. The amount of exudate was cal-
culated by subtracting the volume injected (2 ml) from the total volume
recovered. Leucocytes in the exudate were stained with the vital dye Trypan
Blue and counted with a Bürker chamber. Lung tissue specimens were also
collected and immediately processed as described below.
Evaluation of iNOS and COX-2 expression by
Western blot analysis
Lung tissue fragments were quickly minced and homogenized in 500 l
cold lysis buffer containing 10 mmol/l Tris/HCl pH 7.4, 10 mmol/l NaCl,
1.5 mmol/l MgCl2, 2 mmol/l Na2ethylenediaminetetraacetic acid (EDTA),
1% v/v Triton X-100, 1 mmol/l phenylmethylsulfonyl fluoride, 20 g/ml
leupeptin, 1 g/ml pepstatin, 1 mg/ml pefabloc and 2.5 g/ml aprotinin.
Upon centrifugation at 13,000  g at 4	C for 10 min., the supernatants
were collected and the total protein content was measured spectrophoto-
metrically using micro BCA Protein Assay Reagent Kit (Pierce, IL, USA).
The samples, each containing 100 g of total proteins, were elec-
trophoresed by SDS-PAGE (200 V, 1 hr) using a denaturating 7.6% v/v
polyacrylamide gel and blotted onto nitrocellulose membranes
(Amersham, Buckinghamshire, UK) (150 V, 1 hr). After thorough wash-
ings in PBS containing 0.1% v/v Tween (T-PBS), the membranes were
blocked with T-PBS containing 5% w/v bovine serum albumin at room
temperature for 1 hr and incubated overnight at 4	C with rabbit polyclonal
antisera against iNOS and COX-2, both diluted 1:1000 in T-PBS containing
1% w/v bovine serum albumin. After washing in T-PBS the membranes
were incubated with peroxidase-labelled goat anti-rabbit antibody (Vector,
Burlingame, CA, USA), diluted 1:10,000 in T-PBS containing 1% w/v
bovine serum albumin, for 1 hr at room temperature. Immune reaction
was revealed by incubation with the enhanced chemiluminescent (ECC)
substrate (Amersham) followed by exposure to high sensitivity photo-
graphic film (Biomax ML, Kodak, Rochester, NY, USA). As internal control,
membranes immunostained with rabbit polyclonal anti -actin antibody
(1:20,000) were used. For iNOS and COX-2, quantitative evaluations of the
band intensities were performed by computer-assisted densitometry,
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using the Scion Image Beta 4.0.2 image analysis program (Scion,
Frederick, MD, USA). Each band was then normalized to that of actin.
Determination of nitric oxide synthase activity
The calcium-independent conversion of L-arginine to L-citrulline was
assumed as iNOS activity, according to Cuzzocrea et al. [21]. Lung 
tissue specimens were homogenized in a buffer composed of: 
50 mmol/l Tris-HCl, 0.1 mmol/l EDTA, and 1 mmol/l phenylmethylsul-
fonyl fluoride, pH 7.4, and then used for the L-[3H]arginine to 
L-[3H]citrulline conversion assay. Briefly, 50 l of each sample were
incubated in the presence of 10 mol/l L-[3H]arginine (5 kBq per tube),
1 mmol/l NADPH, 30 nmol/l calmodulin, 5 mol/l tetrahydrobiopterin,
and 2 mmol/l ethylene glycol tetro-acetic acid (EGTA) for 20 min. at
22	C. The reaction was stopped by 0.5 ml ice-cold HEPES buffer, pH 5.5,
containing 2 mmol/l EGTA and 2 mmol/l EDTA. Reaction mixtures were
applied to Dowex 50W (Na form) columns and the eluted L-
[3H]citrulline activity was measured by a scintillation counter (Beckman
Coulter, Inc., Fullerton, CA, USA).
Measurement of nitrites
Total nitrites, the stable end products of nitric oxide, were measured in
the exudate as described previously [18]. Briefly, nitrates in the sample
were first reduced to nitrites by incubation with 280 mU/ml nitrate reduc-
tase and 160 mol/l NADPH at room temperature for 3 hrs. The total
nitrite concentration in the samples was then measured using the Griess
reaction by adding 100 l of Griess reagent (0.1% w/v naphthylethylen-
diamide dihydrochloride in water and 1% w/v sulfanilamide in 5% v/v
H3PO4) to 100 l of the samples. Optical density was measured at 
550 nm wavelength using a microplate reader (SLT-Lab Instruments,
Salzburg, Austria). Nitrite concentrations were calculated by comparison
with a standard curve of sodium nitrite.
Evaluation of cyclooxygenase activity
Lung tissue specimens were homogenized in a buffer composed of: 
20 mmol/l HEPES, pH 7.2, 320 mmol/l sucrose, 1 mmol/l dithiothreitol, 
10 g/ml styrosporin, 2 g/ml aprotinin and 10 g/ml leupeptin. The
homogenates were incubated at 37	C for 30 min. in the presence of excess
arachidonic acid (30 mol/l). The samples were boiled and centrifuged at
10,000  g for 5 min. The concentration of 6-keto-PGF1 in the super-
natant was then measured by radioimmunoassay as previously described
[22]. Protein concentration in each homogenate was measured using the
Bradford assay using a standard curve of bovine serum albumin [23].
Myeloperoxidase (MPO) activity
MPO activity, an indicator of PMN accumulation, was determined as
described previously [24]. Lung tissue specimens were weighed and
homogenized in a buffer composed of: 0.5% w/v hexadecyltrimethyl-
ammonium bromide dissolved in 10 mmol/l potassium phosphate
buffer, pH 7.0, and centrifuged for 30 min. at 20,000  g at 4	C. 
An aliquot of the supernatant was then allowed to react with a solution
of 1.6 mmol/l tetramethylbenzidine and 0.1 mmol/l hydrogen peroxide.
The rate of change in absorbance was measured spectrophotometrically
at 650 nm wavelength. MPO activity was defined as the quantity of
enzyme degrading 1 mol of peroxide per min. at 37	C and was
expressed in mU/g wet tissue.
Thiobarbituric acid-reactive substance (TBARS)
measurement
TBARS levels in the lung tissue, an indicator of lipid peroxidation, were
determined as described previously [25]. Lung tissue specimens were
homogenized in 1.15% w/v KCl solution. A 100 l aliquot of the
homogenate was added to a reaction mixture containing 200 l of 8.1% w/v
SDS, 1.5 ml of 20% v/v acetic acid, pH 3.5, 1.5 ml of 0.8% w/v thiobarbi-
turic acid and 700 l of distilled water. Samples were then boiled for 1 hr 
at 95	C and centrifuged at 3000  g for 10 min. The absorbance of the
supernatant was measured spectrophotometrically at 532 nm wavelength.
Immunohistochemical localization of nitrotyrosine
NT, an index of protein nitrosylation by harmful oxidants generated during
inflammation, such as peroxynitrite, was determined by immunohisto-
chemistry as described previously [21]. Sections from formaldehyde-fixed,
paraffin-embedded lung tissue specimens were rehydrated, endogenous
peroxidase was quenched with 0.3% v/v hydrogen peroxide in 60% v/v
methanol for 30 min., the sections were permeabilized with 0.1% w/v
Triton X-100 in PBS for 20 min., non-specific labelling was minimized by
incubating the section in 2% v/v normal goat serum in PBS for 20 min., the
sections were incubated with rabbit polyclonal anti-NT antiserum (Upstate
Biotechnology, Buckingham, UK; 1:100) at 4	C overnight, immune reaction
was revealed by goat anti-rabbit IgG conjugated with biotin (Vector Lab,
Burlingame, CA, USA; 1:200) followed by incubation with ABC complex
(Vector Lab; 1:200). Negative controls were carried out by omitting the pri-
mary or the secondary antibodies. The sections were counterstained with
haematoxylin before mounting.
Evaluation of nitrotyrosine expression by dot blot
analysis
Samples of lung tissue homogenates, each containing 200 g of total proteins,
were spotted on nitrocellulose membrane strips (Amersham). They were 
air-dried for 30 min. and then saturated with T-PBS containing 5% w/v bovine
serum albumin for 1 hr at room temperature. The strips were subsequently
incubated with rabbit polyclonal antiserum against NT (Upstate), diluted 1:300
in T-PBS containing 1% w/v bovine serum albumin, for 1 hr at room temper-
ature. After washing in T-PBS the membranes were incubated with peroxidase-
labelled goat anti-rabbit antibodies diluted 1:10,000 in T-PBS containing 1% w/v
bovine serum albumin, for 1 hr at room temperature. Immunoreactivity was
revealed by chemiluminescence using the ECL system.
Histological examination
Lung specimens were fixed in 10% w/v PBS-buffered formaldehyde and
embedded in paraffin. Histopathological examination was carried out on
tissue sections, 7 m thick, stained with haematoxylin and eosin.
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Measurement of pro-inflammatory cytokines 
and PGE2
Tumour necrosis factor (TNF)- and IL-1 levels in the pleural exudate
were evaluated using a commercial enzyme-linked immunosorbent assay
kit (Calbiochem-Novabiochem, Milan, Italy) with a lower detection limit of
10 pg/ml. PGE2 levels were measured by radioimmunoassay (Amersham)
without prior extraction, as described previously [26].
Measurement of oxygen free radical scavenging
properties of K5NOSepiLMW
To evaluate whether the observed effects of K5NOSepiLMW could be
attributable to intrinsic oxygen free radical scavenging properties, this sub-
stance was tested in a cell-free system using the xanthine-xanthine oxidase
superoxide anion generating system [27]. Briefly, xanthine oxidase metab-
olizes in vitro its substrate xanthine and generates superoxide anion, which
can be measured spectrophotometrically by the oxidation of the chro-
mogen nitro blue tetrazolium (NBT) to formazan. K5NOSepiLMW was
added to 10, 100 and 1000 g/ml (concentrations in the range of the dose
administered to the rats) to a reaction solution containing 5 mU/ml xan-
thine oxidase, 250 g/ml xanthine and 100 M NBT bromide in phosphate
buffer, pH 7.4. The samples were placed in a thermostat at 37	C and the
reduction of NBT was evaluated spectrophotometrically at 570 nm wave-
length after 5 and 15 min. of incubation.
Statistical analysis
Values are expressed as mean 
 S.E.M. Statistical significance of the dif-
ferences between the experimental groups was checked by of one- or two-
way ANOVA, as appropriate, followed by post hoc test for comparison
between individual groups. A P-value  0.05 was considered significant.
Results
All the rats treated with carrageenan developed an acute pleurisy
characterized by the production of turbid exudate (Fig. 1A).
Compared with the number of PMN collected from the pleural
space of the sham-operated controls, injection of carrageenan
induced a significant increase in the cell number (Fig. 1B). Pre-
treatments of rats with K5NOSepiLMW dose-dependently reduced
Fig. 1 Pleural exudate volume (A) and number of polymorphonuclear
cells, PMN, in the pleural fluid (B) in the different experimental groups,
collected 4 hrs after carrageenan injection. K5NOSepiLMW (0.1–1 mg/kg
b.wt.) and celecoxib (1 mg/kg b.wt.), but not compound B4/110 (1 mg/kg
b.wt.), given 30 min. before carrageenan, significantly reduced these
parameters as compared with carageenan alone. Significance of differ-
ences (one-way ANOVA, n  8): #P  0.001 versus sham-operated con-
trols; *P  0.001 versus carrageenan treated.
Fig. 2 iNOS protein expression evaluated by Western blot analysis in lung
tissue samples from the different experimental groups, collected 4 hrs
after carrageenan injection. Carrageenan increases iNOS expression,
whereas pre-treatment with K5NOSepiLMW (1 mg/kg b.wt.) inhibits this
effect (A). These data are confirmed by densitometric analysis (B).
Significance of differences (one-way ANOVA, n  8): #P  0.001 versus
sham-operated controls; *P  0.001 versus carrageenan treated.
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the volume of the pleural exudate and the number of PMN within
the exudate. These inhibitory effects were also observed when the
rats were pre-treated with celecoxib (1 mg/kg b.wt.) but not with
compound B4/110 (1 mg/kg b.wt.) (Fig. 1A and B).
A significant increase in lung iNOS expression and activity 
was observed 4 hrs after administration of carrageenan (Fig. 2A
and B). Pre-treatment of rats with K5NOSepiLMW significantly
reduced iNOS expression, evaluated by Western blot analysis 
(Fig. 2A), pre-treatment of rats with K5NOSepiLMW (1 mg/kg
b.wt.) or celecoxib (1 mg/kg b.wt.) significantly reduced iNOS
activity, measured as citrulline formation (Fig. 3A) and nitrite pro-
duction (Fig. 3B). B4/110 (1 mg/kg b.wt.) did not cause any
changes in iNOS activity (Fig. 3A and B).
COX-2 expression was evaluated by Western blotting (Fig. 4),
whereas COX-2 activity was determined by measuring the levels
of PGE2 in the exudates (Fig. 5A) and of 6keto-PGF1 in the
supernatant of lung tissue homogenates (Fig. 5B). In comparison
with the sham-operated controls, the amount of COX-2 protein
and the levels of both PGE2 and 6keto-PGF1 were greatly
increased in the carrageenan-treated rats, an effect significantly
and dose-dependently blunted by pre-treatment of the rat with
K5NOSepiLMW and celecoxib (1 mg/kg b.wt.), but not with
B4/110 (1 mg/kg b.wt.).
Carrageenan-treated rats exhibited a substantial increase in
lung tissue MPO and TBARS, assumed as markers for PMN infil-
tration [24] and lipid peroxidation [25], respectively, as 
compared with the sham-operated controls (Fig. 6A and B). 
Pre-treatment of rats with K5NOSepiLMW attenuated in a 
dose-dependent fashion the increase in MPO and TBARS
induced by carrageenan; celecoxib (1 mg/kg b.wt.) had a similar
effect, while B4/110 (1 mg/kg b.wt.) was completely inactive
(Fig. 6A and B).
Immunohistochemical analysis of lung sections obtained from
carrageenan-treated rats revealed a positive staining for NT, which
was absent in lung samples taken from the sham-operated con-
trols (Fig. 7A and B). In contrast, no staining for NT was found in
the lungs of carrageenan-treated rats that had been pre-treated
with K5NOSepiLMW (1 mg/kg b.wt.) (Fig. 7C). Staining was
absent in lungs from the sham-operated controls (not shown).
Fig. 3 iNOS enzyme activity, evaluated as L-[3H]citrulline generation (A)
and nitrite production (B), in lung tissue samples from the different exper-
imental groups, collected 4 hrs after carrageenan injection. Carrageenan
increases iNOS activity whereas pre-treatment with K5NOSepiLMW
inhibits this effect (A, B). Moreover, K5NOSepiLMW (0.1–1 mg/kg b.wt.)
and celecoxib (1 mg/kg b.wt.), but not compound B4/110 (1 mg/kg b.wt.),
significantly reduce iNOS activity as compared with carageenan alone (A,
B). Significance of differences (one-way ANOVA, n  8): #P  0.001
versus sham-operated controls; *P  0.001 versus carrageenan treated.
Fig. 4 COX-2 protein expression evaluated by Western blot analysis in
lung tissue samples from the different experimental groups, collected
4 hrs after carrageenan injection. Carrageenan increases COX-2
expression, whereas pre-treatment with K5NOSepiLMW (1 mg/kg
b.wt.) inhibits this effect (A). These data are confirmed by densitomet-
ric analysis (B). Significance of differences (one-way ANOVA, n  8): 
#P  0.001 versus sham-operated controls; *P  0.001 versus car-
rageenan treated.
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The immunohistochemical data was confirmed by dot blot analy-
sis on lung tissue homogenates, showing that immunoreactive NT
was almost undetectable in the sham-operated controls, was
clearly present at high levels in the carrageenan-treated rats and
became barely detectable upon pre-treatment with K5NOSepiLMW
(1 mg/kg b.wt.) (Fig. 7D).
At variance with the normal histological appearance of the lungs
from the sham-operated controls (Fig. 8A), the specimens from the
rats treated with carrageenan showed tissue oedema, haemorrhage
foci, infiltration with PMN and lymphocytes and reduced alveolar
spaces (Fig. 8B). Pre-treatment K5NOSepiLMW (1 mg/kg b.wt.)
reduced the above lung tissue abnormalities (Fig. 8C).
The levels of the pro-inflammatory cytokines IL-1 and TNF-
were increased in the pleural exudate of the carrageenan-treated
rats compared with the sham-operated controls (Fig. 9A and B).
The levels of both these cytokines were significantly and dose-
dependently reduced upon pre-treatment with K5NOSepiLMW and
celecoxib (1 mg/kg b.wt.), but not with B4/110 (1 mg/kg b.wt.)
(Fig. 9A and B).
K5NOSepiLMW, at any time-point tested, did not influence the
levels of superoxide anion, expressed as mol of formazan, gen-
erated by the xanthine-xanthine oxidase system, thus indicating
that this molecule has no intrinsic oxygen free radical scavenging
properties (5-min. incubation: control, 5.1  1.2; K5NOSepiLMW:
10 g/ml, 4.5  0.6; 100 g/ml, 4.5  1; 1000 g/ml, 3.2  0.3;
P 0.05. 15-min. incubation: control, 9.1  1.4; K5NOSepiLMW:
10 g/ml, 9.5  0.5; 100 g/ml, 7.4  1.5; 1000 g/ml, 6.1 
0.3; P  0.05).
Fig. 5 COX-2 enzyme activity, evaluated as production of PGE2 (A) and 6-
keto-PGF1 (B), in lung tissue samples from the different experimental
groups, collected 4 hrs after carrageenan injection. Carrageenan
increases COX-2 expression, whereas K5NOSepiLMW (0.1–1 mg/kg
b.wt.) and celecoxib (1 mg/kg b.wt.), but not compound B4/110 
(1 mg/kg b.wt.), significantly reduced COX-2 activity as compared with
carageenan alone (A, B). Significance of differences (one-way ANOVA, 
n  8): #P  0.001 versus sham-operated controls; *P  0.001 versus
carrageenan treated.
Fig. 6 Lung tissue myeloperoxidase, MPO, (A) and thiobarbituric acid-
reactive substances, TBARS, (B) in lung tissue samples from the differ-
ent experimental groups, collected 4 hrs after carrageenan injection.
K5NOSepiLMW (0.1–1 mg/kg b.wt.) and celecoxib (1 mg/kg b.wt.), but
not compound B4/110 (1 mg/kg b.wt.), significantly reduced these
parameters as compared with carageenan alone. Significance of differ-
ences (one-way ANOVA, n  8): #P  0.001 versus sham-operated con-
trols; *P  0.001 versus carrageenan treated.
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Discussion
This study provides evidence that a low molecular weight semi-
synthetic O-sulphated heparin derivative (K5NOSepiLMW)
markedly reduces the acute inflammatory response of carrageenan-
induced pleurisy in the rat in vivo, a commonly used animal model
to evaluate the efficacy of non-steroidal anti-inflammatory drugs
(NSAIDs). A 30-min pre-treatment with K5NOSepiLMW, injected
locally at doses of 0.1, 0.5 and 1 mg/kg b.wt., attenuated the
recruitment of inflammatory leucocytes in the lung tissue and the
pleural exudate, inhibited the induction of iNOS and COX-2,
thereby abating the generation of harmful nitric oxide and pro-
inflammatory PGs, such as PgE2 and PGF1 [16, 28], reduced the
inflammation-induced nitroxidative stress, as shown by TBARS
and NT, and blunted the local generation of cytokines such as IL-1
and TNF-. As expected, all these parameters were markedly 
up-regulated by intrapleural injection of carrageenan in the
absence of any pre-treatment. The anti-inflammatory effects of
K5NOSepiLMW appear specific, as judged by the marked dose-
response relationship in the 0.1–1 mg/kg b.wt. range; in this
respect, K5NOSepiLMW is fairly potent, as its effects correspond
to 1 mg/kg b.wt. of celecoxib, a selective COX-2 inhibitor assumed
as reference NSAID. It is conceivable that the observed effect of
K5NOSepiLMW to inhibit COX-2 and PG generation may be due,
Fig. 7 Representative light micrographs of lung tissue immunostained to
reveal nitrotyrosine (NT) in sham-operated rats (A), carrageenan-treated
rats (B) and rats given K5NOSepiLMW (1 mg/kg b.wt.) 30 min. before
carrageenan (C). Carrageenan causes the appearance of a clear-cut NT
immunostaining, whereas K5NOSepiLMW nearly abolishes this effect.
Bars  50 m. Dot blot analysis on lung tissue homogenates (D) shows
that carrageenan treatment increases the amount of NT-containing pro-
teins, whereas pre-treatment with K5NOSepiLMW inhibits this effect.
Fig. 8 Representative light micrographs of lung tissue in sham-operated
controls (A), carrageenan-treated rats (B) and rats given K5NOSepiLMW
(1 mg/kg b.wt.) 30 min. before carrageenan (C). Carrageenan causes the
appearance of tissue oedema, haemorrhage foci, leucocyte infiltration
and reduction of alveolar spaces (arrows), whereas K5NOSepiLMW
blunts these histopathological changes. Asterisks label bronchial lumina.
Bars   100 m.
Fig. 9 Levels of IL-1 (A) and TNF- (B) in the pleural exudates collected
from the different experimental groups, collected 4 hrs after carrageenan
injection.. K5NOSepiLMW (0.1–1 mg/kg b.wt.) and celecoxib (1 mg/kg
b.wt.), but not compound B4/110 (1 mg/kg b.wt.), significantly reduced the
amounts of these pro-inflammatory cytokines as compared with carageenan
alone. Significance of differences (one-way ANOVA, n  8): #P  0.001
versus sham-operated controls; *P  0.001 versus carrageenan treated.
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at least in part, to inhibition of iNOS activity and nitric oxide pro-
duction, as nitric oxide can activate COX-2 activity [29]. On the
other hand, the current findings allow ruling out that the observed
protection from lung inflammation afforded by K5NOSepiLMW
may be related to oxygen free radical scavenging properties, as
this molecule was unable to decrease the levels of superoxide
anion generated by an in vitro free radical generating system, such
as xanthine-xanthine oxidase.
The current findings are in keeping with previous studies
showing that low molecular weight heparins are capable of func-
tionally inhibiting the cells of acute and chronic inflammatory
response, decreasing PMN and monocyte chemotaxis and activa-
tion [30–32] and inhibiting fibroblast proliferation, endothelial
activation and neo-angiogenesis [33–35]. The low molecular
weight of K5NOSepi is a useful feature for the anti-inflammatory
activity of this substance, as it may allow this molecule to enter
the target cells where it exerts its anti-inflammatory effects by
interfering with the expression of pro-inflammatory cytokines
[14]. This assumption is in keeping with previous reports that low
molecular weight heparins and non-anticoagulant heparins blunt
pro-inflammatory cytokine generation by inhibiting nuclear
translocation of the transcription factor NF-B [32, 36], although
we have no direct evidence that such mechanism of action is also
operating in K5NOSepiLMW. As IL-1 and TNF- are known to
mediate the induction of iNOS and COX-2 [37, 38], it is conceiv-
able that the reduced levels of these inducible pro-inflammatory
enzymes observed in the present study may be secondary to a
reduced formation of endogenous IL-1 and TNF- by
K5NOSepiLMW. The possibility that K5NOSepiLMW could directly
inhibit iNOS and COX-2 activity cannot be ruled out, but the pres-
ent findings do not allow clarifying this issue. Moreover, the
marked anti-inflammatory properties of K5NOSepiLMW appear to
be related to O-sulphation, which enable it to bind to and inacti-
vate endothelial L- and P-selectins, thus counteracting leucocyte
rolling and adhesion [13].
In conclusion, this study provides support to the concept that
semi-synthetic, low molecular weight heparin derivatives may rep-
resent a novel class of potent NSAIDs which, compared with
unfractionated full-sized heparins, lack pro-angiogenic properties
and substantial effects on the coagulation system [39]. Based on
its specific pharmacological effects highlighted in the present
study, K5NOSepiLMW could be suitable as an endothelial protect-
ing drug for the treatment of vascular inflammation, potentially
useful for the prevention of cardiovascular disease, which encom-
passes hypertension, atherothrombosis, myocardial infarction,
stroke, peripheral vascular disease and renal failure.
Acknowledgement
This investigation was supported by a grant from the Ente Cassa di
Risparmio di Firenze, Florence, Italy.
References
1. Xie WL, Chipman JG, Robertson DL, 
et al. Expression of a mitogen-responsive
gene encoding prostaglandin synthase is
regulated by mRNA splicing. Proc Natl
Acad Sci USA. 1991; 88: 2692–6.
2. Sluiter W, Pietersma A, Lamers JMJ, 
et al. Leukocyte adhesion molecules on
the vascular endothelium: their role in the
pathogenesis of cardiovascular disease
and the mechanism underlying their
expression. J Cardiovasc Pharmacol.
1993; 22: S37–44.
3. Laroux FS, Lefer DJ, Kawachi S, et al.
Role of nitric oxide in the regulation of
acute and chronic inflammation. Antiox
Redox Signal. 2000; 2: 391–6.
4. Johnson KJ, Varani J, Smolen JE.
Neutrophil activation and function in health
and disease. Immunol Ser. 1992; 57: 1–46.
5. Feuerstein G, Hallenbeck JM. Prostag -
landins, leukotrienes, and platelet-activat-
ing factor in shock. Annu Rev Pharmacol
Toxicol. 1987; 27: 301–13.
6. Tomlinson A, Appleton I, Moore AR, 
et al. Cyclo-oxygenase and nitric oxide
synthase isoforms in rat carrageenin-
induced pleurisy. Br J Pharmacol. 1994;
113: 693–8.
7. Guyton JR, Rosenberg RD, Clowes AW,
et al. Inhibition of rat arterial smooth mus-
cle cell proliferation by heparin. In vivo
studies with anticoagulant and nonantico-
agulant heparin. Circ Res. 1980; 46:
625–34.
8. Folkman J. Regulation of angiogenesis: a
new function of heparin. Biochem
Pharmacol. 1985; 34: 905–9.
9. Au YP, Montgomery KF, Clowes AW.
Heparin inhibits collagenase gene expres-
sion mediated by phorbol ester-responsive
element in primate arterial smooth muscle
cells. Circ Res. 1992; 70: 1062–9.
10. Weiler JM, Edens RE, Linhardt RJ, et al.
Heparin and modified heparin inhibit com-
plement activation in vivo. J Immunol.
1992; 148: 3210–5.
11. Nelson RM, Cecconi O, Roberts WG, 
et al. Heparin oligosaccharides bind 
L- and P-selectin and inhibit acute inflam-
mation. Blood. 1993; 82: 3253–8.
12. Attanasio M, Gori AM, Giusti B, et al.
Cytokine gene expression in human LPS-
and IFNgamma-stimulated mononuclear
cells is inhibited by heparin. Thromb
Haemost. 1998; 79: 959–62.
13. Wang JG, Mu JS, Zhu HS, et al.
N-desulfated non-anticoagulant heparin
inhibits leukocyte adhesion and transmi-
gration in vitro and attenuates acute peri-
tonitis and ischemia and reperfusion
injury in vivo. Inflamm Res. 2002; 51:
435–43.
14. Gori AM, Attanasio M, Gazzini A, et al.
Cytokine gene expression and production
by human LPS-stimulated mononuclear
cells are inhibited by sulfated heparin-like
semi-synthetic derivatives. J Thromb
Haemost. 2004; 2: 1657–62.
15. Gilroy DW, Colville-Nash PR, Willis D, 
et al. Inducible cyclooxygenase may have
anti-inflammatory properties. Nat Med.
1999; 5: 698–701.
16. Cuzzocrea S, Mazzon E, Calabro G, et al.
Inducible nitric oxide synthase-knockout
mice exhibit resistance to pleurisy and
lung injury caused by carrageenan. Am J
Respir Crit Care Med. 2000; 162:
1859–66.
2712 © 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
17. Cuzzocrea S, Santagati S, Sautebin L, 
et al. 17beta-estradiol antiinflammatory
activity in carrageenan-induced pleurisy.
Endocrinology. 2000; 141: 1455–63.
18. Cuzzocrea S, Mazzon E, Sautebin L, et al.
The protective role of endogenous estro-
gens in carrageenan-induced lung injury in
the rat. Mol Med. 2001; 7: 478–87.
19. Cuzzocrea S, Mazzon E, Sautebin L, 
et al. Protective effects of Celecoxib on
lung injury and red blood cells modifica-
tion induced by carrageenan in the rat.
Biochem Pharmacol. 2002; 63: 785–95.
20. Cuzzocrea S, McDonald MC, Mazzon E,
et al. Effects of 5-aminoisoquinolinone, a
water-soluble, potent inhibitor of the activ-
ity of poly (ADP-ribose) polymerase, in a
rodent model of lung injury. Biochem
Pharmacol. 2002; 63: 293–304.
21. Cuzzocrea S, Zingarelli B, Hake P, et al.
Antiinflammatory effects of mercaptoethyl-
guanidine, a combined inhibitor of nitric
oxide synthase and peroxynitrite scav-
enger, in carrageenan-induced models of
inflammation. Free Radic Bio Med. 1998;
24: 450–9.
22. Tomlinson A, Appleton I, Moore AR, et al.
Cyclo-oxygenase and nitric oxide synthase
isoforms in rat carrageenin-induced
pleurisy. Br J Pharmacol. 1994; 113: 693–8.
23. Bradford MM. A rapid and sensitive
method for the quantitation of microgram
quantities of protein utilizing the principle
of protein-dye binding. Anal Biochem.
1976; 72: 248–54.
24. Mullane KM, Kraemer R, Smith B.
Myeloperoxidase activity as a quantitative
assessment of neutrophil infiltration into
ischemic myocardium. J Pharmacol
Methods. 1985; 14: 157–67.
25. Ohkawa H, Ohishi N, Yagi K. Assay for
lipid peroxides in animal tissues by thio-
barbituric acid reaction. Anal Biochem.
1979; 95: 351–8.
26. Sautebin L, Ialenti A, Ianaro A, et al.
Endogenous nitric oxide increases
prostaglandin biosynthesis in carrageenin
rat paw oedema. Eur J Pharmacol. 1995;
286: 219–22.
27. Goldstein IM, Kaplan HB, Edelson HS, 
et al. Ceruloplasmin: an acute phase reac-
tant that scavenges oxygen-derived free
radicals. Ann N Y Acad Sci. 1982; 389:
368–79.
28. Harada Y, Hatanaka K, Kawamura M, 
et al. Role of prostaglandin H synthase-2 in
prostaglandin E2 formation in rat car-
rageenin-induced pleurisy. Prostaglandins.
1996; 51: 19–33.
29. Salvemini D, Misko TP, Masferrer JL, 
et al. Nitric oxide activates cyclooxyge-
nase enzymes. Proc Natl Acad Sci U S A.
1993; 90: 7240–4.
30. Matzner Y, Marx G, Drexler R, et al. The
inhibitory effect of heparin and related gly-
cosaminoglycans on neutrophil chemo-
taxis. Thromb Haemost. 1984; 52: 134–7.
31. Tangelder GJ, Arfors KE. Inhibition of
leukocyte rolling in venules by protamine
and sulfated polysaccharides. Blood. 1991;
77: 1565–71.
32. Hochart H, Jenkins PV, Smith OP, et al.
Low-molecular weight and unfractionated
heparins induce a downregulation of
inflammation: decreased levels of proin-
flammatory cytokines and nuclear factor-
kappaB in LPS-stimulated human mono-
cytes. Br J Haematol. 2006; 133: 62–7.
33. Bârzu T, Lormeau JC, Petitou M, et al.
Heparin-derived oligosaccharides: affinity
for acidic fibroblast growth factor and
effect on its growth-promoting activity for
human endothelial cells. J Cell Physiol.
1989; 140: 538–48.
34. Deepa PR, Varalakshmi P. Favourable
modulation of the inflammatory changes in
hypercholesterolemic atherogenesis by a
low-molecular-weight heparin derivative.
Int J Cardiol. 2006; 106: 338–47.
35. Norrby K. Low-molecular-weight heparins
and angiogenesis. Acta Pathol Microbiol
Immunol Scand. 2006; 114: 79–102.
36. Thourani VH, Brar SS, Kennedy TP, et al.
Nonanticoagulant heparin inhibits NF-
kappaB activation and attenuates myocar-
dial reperfusion injury. Am J Physiol Heart
Circ Physiol. 2000; 278: H2084–93.
37. Szabo C, Wu CC, Gross SS, et al.
Interleukin-1 contributes to the induction
of nitric oxide synthase by endotoxin in
vivo. Eur J Pharmacol. 1993; 250: 157–60.
38. Akarasereenont P, Bakhle YS,
Thiemermann C, et al. Cytokine-mediated
induction of cyclo-oxygenase-2 by activa-
tion of tyrosine kinase in bovine endothe-
lial cells stimulated by bacterial
lipopolysaccharide. Br J Pharmacol. 1995;
115: 401–8.
39. Schulman S. Novel anticoagulant agents:
introduction. J Intern Med. 2003; 254:
308–12.
